Sort   by:  
 Page size 
MetabolomicsExploring Lipidomic Profiles and Their Correlation with Hormone Receptor and HER2 Status in Breast Cancer
Dysregulated lipid metabolism promotes the progression of various cancers, including breast cancer. This study aimed to explore the lipidomic profiles of breast cancer patients, providing insights into the correlation between lipid compositions and tumor subtypes characterized by hormone receptor (H...
2024-08-16 | MTBLS10858 | MetaboLights
MetabolomicsIntegrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiency
Functional oncogenic links between ErbB2 and ERRα in HER2+ breast cancer patients support a therapeutic benefit of co-targeted therapies. However, ErbB2 and ERRα also play key roles in heart physiology, and this approach could pose a potential liability to cardiovascular health. Herein, using integr...
2022-09-20 | MTBLS795 | MetaboLights
ProteomicsProteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Resistance to Human Epidermal Growth Factor Receptor (HER)-targeted cancer therapies appear to be occurring via common pathways, despite differences in their mechanism of action. This suggests that combination therapies targeting alternative pathways will be needed to overcome resistance. We have us...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-28 | MSV000080706 | MassIVE
TranscriptomicsA Splice Variant of HER2 Activates Key Signaling Cascades and Evokes Mammary Tumors and Metastases
The Epidermal Growth Factor Receptor 2 (ERBB2 or HER2) is amplified and overexpressed in approximately 20% of invasive breast cancers and is associated with metastasis and poor prognosis. Here we describe the role of a constitutively active splice variant of HER2 (Delta-HER2) in human mammary epithe...
ORGANISM(S): Homo sapiens 
2013-10-22 | E-GEOD-42781 | biostudies-arrayexpress
TranscriptomicsHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...
ORGANISM(S): Homo sapiens 
2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress
TranscriptomicsMutant PI3K cooperates with HER2 to promote mammary tumor formation and induces trastuzumab resistance in vivo
HER2 (ERBB2) gene amplification and PIK3CA mutations often co-occur in breast cancer, and aberrant activation of the PI3K pathway has been implicated in resistance to HER2-directed therapies. We have created a mouse model of HER2-overexpressing (HER2+), PIK3CAH1047R-mutant breast cancer. Mice expres...
ORGANISM(S): Mus musculus 
2013-09-03 | E-GEOD-41118 | biostudies-arrayexpress
ProteomicsIdentification of HER2 peptides for quantification in formalin-fixed paraffin-embedded breast cancer tissues
The ability to accurately quantify proteins in formalin-fixed paraffin-embedded (FFPE) tissues using targeted mass spectrometry opens exciting perspectives for biomarker discovery. We have developed and evaluated a selected reaction monitoring (SRM) assay for the human receptor tyrosine-protein kina...
ORGANISM(S): Homo sapiens (Human) 
2015-07-16 | PXD002281 | Pride
Breast cancer Human receptor tyrosine-protein kinase erbb-2 (her2) Human Ltq orbitrap velos Formalin-fixed parrafin-embedded tissues (ffpe) 
TranscriptomicsTranscription profiling of MCF-7 cell lines stably overexpressing constitutively active Raf-1, constitutively active MEK, constitutively active c-erbB-2, or ligand-activatable EGFR as models of overexpressed growth factor signaling
Profiling of MCF-7 cell lines stably overexpressing constitutively active Raf-1, constitutively active MEK, constitutively active c-erbB-2, or ligand-activatable EGFR as models of overexpressed growth factor signaling, as well as control vector transfected cells (coMCF-7) and control vector transfec...
ORGANISM(S): Homo sapiens 
2007-10-02 | E-GEOD-3542 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of mouse mammary tumour samples derived from our MMTV/neundl-NYPD, -YB, -YC, -YD, -YE and the parental MMTV/neu NDL2-5 strains
ErbB-2 overexpression and amplification occurs in 15 - 30% of human invasive breast carcinomas associated with poor clinical prognosis. Previously, we have demonstrated that four ErbB-2/Neu tyrosine-autophosphorylation sites within the cytoplasmic tail of the receptor recruit distinct adaptor pro...
ORGANISM(S): Mus musculus 
2008-06-15 | E-GEOD-7595 | biostudies-arrayexpress
TranscriptomicsMicroRNA signatures predict Estrogen receptor, Progesterone receptor and HER2/neu receptor status in Breast Cancer
Breast cancer is a heterogeneous disease encompassing a number of phenotypically diverse tumours. Expression levels of the estrogen, progesterone and HER2/neu receptors which characterise clinically distinct breast tumors have been shown to change during disease progression and in response to system...
ORGANISM(S): Homo sapiens 
2010-05-18 | E-GEOD-15885 | biostudies-arrayexpress
Sort   by:  
 Page size